Skip to content
Clinical Trials – home

Centre Hospitalier Saint Joseph Saint Luc

Verified siteinfo

France 20 Quai Claude Bernard, 69007 Lyon, France

  • 15 trials recruiting
  • Arteriosclerosis · Colon cancer · Giant cell arteritis
  • Adult patients

About Specializations

Centre Hospitalier Saint Joseph Saint Luc in Lyon, France specialises in clinical trials of conditions such as Arteriosclerosis, Colon cancer, Giant cell arteritis, Hypertriglyceridaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases and Colorectal Cancer Research

At Centre Hospitalier Saint Joseph Saint Luc, clinical research in hepatogastroenterology includes studies focused on digestive system diseases, especially colon carcinoma. These trials are designed to evaluate whether new treatment strategies can improve survival and disease control for patients with locally advanced but resectable disease.

  • Testing a neoadjuvant chemotherapy approach before surgery for colon cancer
  • Comparing treatment pathways to see whether a pre-surgery strategy improves long-term outcomes
  • Supporting more personalized care for older adults with colorectal cancer

This area of research aims to refine how colon carcinoma is managed, with a strong emphasis on treatment effectiveness and survival after surgery.

Cardiovascular Diseases and Heart Attack Prevention

The site also conducts trials in cardiovascular diseases, including acute coronary syndrome, acute myocardial infarction, and ST segment elevation myocardial infarction. These studies are exploring ways to reduce the risk of serious recurrent events after a heart attack and improve recovery for patients with recent cardiac injury.

  • Evaluating a new therapy to lower the risk of major adverse cardiovascular events
  • Studying treatment options after myocardial infarction to prevent future complications
  • Assessing whether cardiac function can be better preserved after ST-elevation myocardial infarction

Research in this field combines prevention and recovery goals, with the aim of improving outcomes for patients at risk of further cardiovascular events.

Cardiac Recovery Imaging and Post-Heart Attack Care

Another important line of research at this hospital examines how treatments may support heart muscle recovery after acute anterior STEMI. The focus is on evaluating whether adding a targeted therapy can improve left ventricular systolic function and support better cardiac performance over time.

  • Comparing a new treatment approach with placebo in patients after ST-elevation myocardial infarction
  • Using cardiac magnetic resonance to assess heart function after treatment
  • Exploring strategies to improve recovery of the injured myocardium

This work highlights a blend of therapeutic and diagnostic research, with the goal of better understanding and improving recovery after severe heart attack.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
20 Quai Claude Bernard69007 LyonFrance
Recruiting now
15 trials
Conditions studied
27
Partner status
Verified site

More sites in LyonFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

33 clinical trials

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Sepsis

Recruiting

Study of dexmedetomidine and a drug combination for treating patients on mechanical ventilation with septic shock.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Hospices Civils De Lyon

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Assistance Publique Hopitaux De Paris

Myocarditis

Recruiting

Study on Colchicine for Reducing Heart Damage in Patients with Acute Myocarditis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Colchicine
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Hospices Civils De Lyon

Neoplasm

Recruiting

Continued Cancer Treatment Study with Abiraterone, Ipatasertib, Tiragolumab, and Drug Combination for Patients from Previous Genentech/Roche Trials

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.